Delcath Systems, Inc. (NASDAQ:DCTH) Receives $22.17 Consensus Price Target from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $22.1667.

DCTH has been the subject of a number of research reports. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, May 11th. BTIG Research reiterated a “buy” rating and issued a $17.00 price target on shares of Delcath Systems in a report on Monday, July 13th. Finally, Zacks Research upgraded shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in DCTH. California State Teachers Retirement System acquired a new position in Delcath Systems during the second quarter valued at $26,000. Russell Investments Group Ltd. acquired a new stake in Delcath Systems during the 3rd quarter worth about $29,000. Tower Research Capital LLC TRC acquired a new stake in Delcath Systems during the 2nd quarter worth about $40,000. Legal & General Group Plc purchased a new position in shares of Delcath Systems during the 2nd quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Delcath Systems during the 2nd quarter valued at about $151,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Price Performance

NASDAQ DCTH opened at $12.63 on Thursday. The company has a market cap of $436.01 million, a price-to-earnings ratio of 1,263.00 and a beta of 0.52. The stock’s fifty day moving average price is $12.18 and its 200 day moving average price is $10.81. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $13.74.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. The company had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. Research analysts expect that Delcath Systems will post -0.88 earnings per share for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.